Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 43

1.

Efficacy and Safety of an Herbal Therapy in Patients with Amnestic Mild Cognitive Impairment: A 24-Week Randomized Phase III Trial.

Tian J, Shi J, Li T, Li L, Wang Z, Li X, Lv Z, Zheng Q, Wei M, Wang Y.

Evid Based Complement Alternat Med. 2017;2017:4251747. doi: 10.1155/2017/4251747. Epub 2017 May 17.

2.

Randomized controlled trials in mild cognitive impairment: Sources of variability.

Petersen RC, Thomas RG, Aisen PS, Mohs RC, Carrillo MC, Albert MS; Alzheimer's Disease Neuroimaging Initiative (ADNI) and Foundation for NIH (FNIH) Biomarkers Consortium AD MCI Placebo Data Analysis Project Team.

Neurology. 2017 May 2;88(18):1751-1758. doi: 10.1212/WNL.0000000000003907. Epub 2017 Apr 5.

3.

From mild cognitive impairment to subjective cognitive decline: conceptual and methodological evolution.

Cheng YW, Chen TF, Chiu MJ.

Neuropsychiatr Dis Treat. 2017 Feb 16;13:491-498. doi: 10.2147/NDT.S123428. eCollection 2017. Review.

4.

Six psychotropics for pre-symptomatic & early Alzheimer's (MCI), Parkinson's, and Huntington's disease modification.

Lauterbach EC.

Neural Regen Res. 2016 Nov;11(11):1712-1726. doi: 10.4103/1673-5374.194708. Review.

5.
6.

Mild Cognitive Impairment.

Petersen RC.

Continuum (Minneap Minn). 2016 Apr;22(2 Dementia):404-18. doi: 10.1212/CON.0000000000000313. Review.

7.

ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials.

Wang J, Logovinsky V, Hendrix SB, Stanworth SH, Perdomo C, Xu L, Dhadda S, Do I, Rabe M, Luthman J, Cummings J, Satlin A.

J Neurol Neurosurg Psychiatry. 2016 Sep;87(9):993-9. doi: 10.1136/jnnp-2015-312383. Epub 2016 Mar 23.

8.

Treatment for mild cognitive impairment: a systematic review and meta-analysis.

Fitzpatrick-Lewis D, Warren R, Ali MU, Sherifali D, Raina P.

CMAJ Open. 2015 Dec 1;3(4):E419-27. doi: 10.9778/cmajo.20150057. eCollection 2015 Oct-Dec.

9.

Recommendations on screening for cognitive impairment in older adults.

Canadian Task Force on Preventive Health Care, Pottie K, Rahal R, Jaramillo A, Birtwhistle R, Thombs BD, Singh H, Connor Gorber S, Dunfield L, Shane A, Bacchus M, Bell N, Tonelli M.

CMAJ. 2016 Jan 5;188(1):37-46. doi: 10.1503/cmaj.141165. Epub 2015 Nov 30. No abstract available.

10.

The diagnosis and management of mild cognitive impairment: a clinical review.

Langa KM, Levine DA.

JAMA. 2014 Dec 17;312(23):2551-61. doi: 10.1001/jama.2014.13806. Review.

11.

A Food and Drug Administration-approved asthma therapeutic agent impacts amyloid β in the brain in a transgenic model of Alzheimer disease.

Hori Y, Takeda S, Cho H, Wegmann S, Shoup TM, Takahashi K, Irimia D, Elmaleh DR, Hyman BT, Hudry E.

J Biol Chem. 2015 Jan 23;290(4):1966-78. doi: 10.1074/jbc.M114.586602. Epub 2014 Dec 2.

12.

Geriatric Psychiatry: What's in a Name, and Five Concerns about DSM-5.

Rapoport MJ.

Can Geriatr J. 2014 Dec 2;17(4):115-7. doi: 10.5770/cgj.17.117. eCollection 2014 Dec. No abstract available.

13.

Neural substrates of cognitive subtypes in Parkinson's disease: a 3-year longitudinal study.

Shoji Y, Nishio Y, Baba T, Uchiyama M, Yokoi K, Ishioka T, Hosokai Y, Hirayama K, Fukuda H, Aoki M, Hasegawa T, Takeda A, Mori E.

PLoS One. 2014 Oct 20;9(10):e110547. doi: 10.1371/journal.pone.0110547. eCollection 2014.

14.

Mild cognitive impairment and mild dementia: a clinical perspective.

Knopman DS, Petersen RC.

Mayo Clin Proc. 2014 Oct;89(10):1452-9. doi: 10.1016/j.mayocp.2014.06.019.

15.

Mild cognitive impairment: diagnosis, longitudinal course, and emerging treatments.

Vega JN, Newhouse PA.

Curr Psychiatry Rep. 2014 Oct;16(10):490. doi: 10.1007/s11920-014-0490-8. Review.

16.

Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014.

Schneider LS, Mangialasche F, Andreasen N, Feldman H, Giacobini E, Jones R, Mantua V, Mecocci P, Pani L, Winblad B, Kivipelto M.

J Intern Med. 2014 Mar;275(3):251-83. doi: 10.1111/joim.12191. Review.

17.

Latent information in fluency lists predicts functional decline in persons at risk for Alzheimer disease.

Clark DG, Kapur P, Geldmacher DS, Brockington JC, Harrell L, DeRamus TP, Blanton PD, Lokken K, Nicholas AP, Marson DC.

Cortex. 2014 Jun;55:202-18. doi: 10.1016/j.cortex.2013.12.013. Epub 2014 Jan 16.

18.

Treatment for mild cognitive impairment: systematic review.

Cooper C, Li R, Lyketsos C, Livingston G.

Br J Psychiatry. 2013 Sep;203(3):255-64. doi: 10.1192/bjp.bp.113.127811. Review. Erratum in: Br J Psychiatry. 2014 Jan;204(1):81.

19.

Prediction of outcomes in MCI with (123)I-IMP-CBF SPECT: a multicenter prospective cohort study.

Ito K, Mori E, Fukuyama H, Ishii K, Washimi Y, Asada T, Mori S, Meguro K, Kitamura S, Hanyu H, Nakano S, Matsuda H, Kuwabara Y, Hashikawa K, Momose T, Uchida Y, Hatazawa J, Minoshima S, Kosaka K, Yamada T, Yonekura Y; J-COSMIC Study Group.

Ann Nucl Med. 2013 Dec;27(10):898-906. doi: 10.1007/s12149-013-0768-7. Epub 2013 Sep 6.

20.

Efficacy and safety of cognitive enhancers for patients with mild cognitive impairment: a systematic review and meta-analysis.

Tricco AC, Soobiah C, Berliner S, Ho JM, Ng CH, Ashoor HM, Chen MH, Hemmelgarn B, Straus SE.

CMAJ. 2013 Nov 5;185(16):1393-401. doi: 10.1503/cmaj.130451. Epub 2013 Sep 16. Review.

Supplemental Content

Support Center